logo-loader
viewCapricor Therapeutics

Capricor Therapeutics working on drug to treat a rare disorder DMD

Capricor Therapeutics (NASDAQ:CAPR) CFO AJ Bergmann joined Steve Darling and Proactive investors in California to talk about their drug for treating a rare childhood disease called Duchenne muscular dystrophy. That drug is entering Phase two of testing.

Bergmann also gave Proactive details on another drug they are working on to deal with Inflammatory and Fibriotic disorders.

Quick facts: Capricor Therapeutics

Price: 2.57 USD

NASDAQ:CAPR
Market: NASDAQ
Market Cap: $9.99 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks struggle as analysts cautious on Canadian sector

The North American Marijuana Index moved 2.3% lower to 128.9 points. The OTCQX Cannabis Index fell 0.4% to 495 points. Buds today were  The Green Organic Dutchman Holdings Ltd (TSE:TGOD) (OTCMKTS:TGODF), CannaRoyaltyCorp (CSE:OH) (OTCMKTS:ORHOF).  Duds were Hexo Corp...

12 hours, 19 minutes ago

2 min read